NEW YORK, August 8, 2017 /PRNewswire/ --
If you want a Stock Review on BABY, MASI, SPNC or ACRX then come over tohttp://dailystocktracker.com/register/ and sign up for your free customized report today. The global Medical Equipment market is expected to reach over $500 billion in 2020, according to a ReportBuyer report. One of
California headquartered Natus Medical Inc.'s stock finished Monday's session 1.00% lower at $34.55 with a total trading volume of 229,182 shares. Over the previous three months, the Company's shares have advanced 0.58%. The stock is trading below its 50-day moving average by 4.59%. Moreover, shares of Natus Medical, which provides newborn care and neurology healthcare products and services worldwide, have a Relative Strength Index (RSI) of 33.64.
On July 26th, 2017, Natus Medical announced financial results for the three and six months ended June 30th, 2017. For Q2 2017, revenue was $122.2 million, GAAP gross profit margin was 54.1%, and GAAP net loss was $5.0 million. For the six months ended June 30th, 2017, the Company reported revenue of $246.9 million, GAAP gross profit margin of 53.8%, and GAAP net loss of $4.7 million. Your complete research report on BABY can be retrieved for free at:
Shares in California headquartered Masimo Corp. rose 1.03%, ending yesterday's session at $86.17. A total volume of 608,264 shares was traded, which was above their three months average volume of 553,970 shares. The stock has gained 0.44% in the previous three months and 27.85% on an YTD basis. The Company's shares are trading 5.73% above their 200-day moving average. Moreover, shares of Masimo, which develops, manufactures, and markets noninvasive monitoring technologies worldwide, have an RSI of 34.74.
On August 02nd, 2017, Masimo announced its financial results for Q2 ended July 01st, 2017. Product revenues for Q2 2017 were $182.8 million, total revenue was $192.9 million, worldwide direct product revenue rose by 13.8%, and net income was $46.7 million. As of July 01st, 2017, total cash and cash investments were $331.4 million. The Company also used $14.4 million in cash from operations, and received $48.2 million in proceeds from stock option exercises during the quarter. A free report on MASI is just a click away at:
On Monday, Colorado headquartered The Spectranetics Corp.'s stock saw a slight drop of 0.13%, to close the day at $38.45. A total volume of 215,670 shares was traded. The Company's shares have advanced 0.13% in the last one month, 37.32% in the previous three months, and 56.94% on an YTD basis. The stock is trading 13.31% and 37.75% above its 50-day and 200-day moving averages, respectively. Additionally, shares of Spectranetics, which together with its subsidiaries, develops, manufactures, markets, and distributes single-use medical devices used in minimally invasive procedures in the cardiovascular system, have an RSI of 80.56.
On August 03rd, 2017, Spectranetics reported financial results for the three months ended June 30th, 2017. Highlights of the quarter included revenue of $74.7 million, Vascular Intervention revenue of $51.0 million, and Lead Management revenue of $19.7 million. Net loss for Q2 2017 was $24.6 million, or $0.56 per share, compared with net loss of $14.9 million, or $0.35 per share, for Q2 2016.
On August 04th, 2017, research firm Needham downgraded the Company's stock rating from 'Buy' to 'Hold'. Sign up for your complimentary research report on SPNC at:
Shares in California headquartered AcelRx Pharmaceuticals Inc. ended the day 1.72% higher at $2.95. A total volume of 852,258 shares was traded. The stock has gained 40.48% in the last one month, 3.51% in the previous three months, and 13.46% since the start of this year. The Company's shares are trading above their 50-day and 200-day moving averages by 12.92% and 4.94%, respectively. Furthermore, shares of AcelRx Pharma, which focuses on the development and commercialization of therapies for the treatment of acute pain, have an RSI of 50.11.
On July 14th, 2017, research firm Jefferies resumed its 'Buy' rating on the Company's stock, with a target price of $7 per share.
On August 01st, 2017, AcelRx Pharma reported financial results for the three and six months ended June 30th, 2017. For Q2 2017, net loss was $13.1 million, and revenue was $2.2 million. Year-to-date financial results included net loss of $28.6 million, and revenue of $5.2 million. As of June 30th, 2017, the Company had cash, cash equivalents and investments of $62.1 million. A free report on ACRX is just a click away at:
Daily Stock Tracker:
Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
DST has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: firstname.lastname@example.org Phone number: (207)331-3313 Office Address: 377 Rivonia Boulevard, Rivonia, South Africa
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA
Subscribe to our Free Newsletters!
Aniridia is a genetic eye disorder in which the iris is partially or entirely absent. It is ...
Cachexia refers to severe muscle and fat loss, anorexia and marked weight loss due to an underlying ...
Exotropia or outward eye deviation is a form of squint. Proper evaluation and timely intervention ...View All